We are live on ! Find out more
OMC

OUP Management Company Portfolio holdings

AUM $44.5M
1-Year Est. Return 55.11%
This Fund
S&P 500
This Quarter Est. Return
+21.9%
1 Year Est. Return
+55.11%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$61.3M
AUM Growth
-$2.96M
Cap. Flow
-$8.76M
Cap. Flow %
-14.31%
Top 10 Hldgs %
96.86%
Holding
16
New
1
Increased
–
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
PRME icon
Prime Medicine
PRME
+$2.19M

Top Sells

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$8.75M
2
EVLV icon
Evolv Technologies
EVLV
+$1.38M
3
LABP
Landos Biopharma, Inc. Common Stock
LABP
+$804K
4
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$16K

Sector Composition

Rank Sector Weight
1 Healthcare 93.37%
2 Technology 6.63%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JBIO
1
Jade Biosciences
JBIO
$1.34B
$17.7M 28.88%
17,250
– –
CNTA
2
DELISTED
Centessa Pharmaceuticals
CNTA
$9.11M 14.87%
2,937,615
– –
PMVP icon
3
PMV Pharmaceuticals
PMVP
$61.3M
$8.61M 14.05%
989,232
– –
DICE
4
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$8.37M 13.67%
268,346
-268,347
-50% -$8.75M
IONQ icon
5
IonQ
IONQ
$15.1B
$4.06M 6.63%
1,177,597
– –
CYT
6
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$4.06M 6.63%
2,459,572
-10,000
-0.4% -$16K
VOR icon
7
Vor Biopharma
VOR
$1.25B
$2.49M 4.07%
18,736
– –
PRME icon
8
Prime Medicine
PRME
$527M
$2.25M 3.68%
+121,255
New +$2.19M
LENZ
9
LENZ Therapeutics
LENZ
$162M
$1.35M 2.2%
58,044
– –
DTIL icon
10
Precision BioSciences
DTIL
$188M
$1.34M 2.18%
37,464
– –
RNAC icon
11
Cartesian Therapeutics
RNAC
$253M
$975K 1.59%
28,751
– –
EFTR
12
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$439K 0.72%
41,028
– –
SPRO icon
13
Spero Therapeutics
SPRO
$72.4M
$431K 0.7%
249,070
– –
QTTB icon
14
Q32 Bio
QTTB
$482M
$80.6K 0.13%
3,556
– –
EVLV icon
15
Evolv Technologies
EVLV
$1.07B
– –
-652,475
Closed -$1.38M
LABP
16
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
– –
-123,767
Closed -$804K

Similar funds

JMF
Johnson Midwest Financial Glidden, Iowa $44.7M AUM 21.66% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
MCAV
Meritech Capital Associates VI Palo Alto, California $45.3M AUM 4.6% 1-Year Est. Return
SIP
Scott Investment Partners Henley-On-Thames, United Kingdom $43.5M AUM 17.97% 1-Year Est. Return
KXA
KPCB XIV Associates Menlo Park, California $42.8M AUM 16.52% 1-Year Est. Return
WRCAI
West Rim Capital Associates II Lehi, Utah $46.8M AUM 11.72% 1-Year Est. Return
MAM
Must Asset Management Seoul, South Korea $40.9M AUM 22.53% 1-Year Est. Return
GIA
G2VP I Associates Portola Valley, California $48.2M AUM 37.59% 1-Year Est. Return

OUP Management Company's Q4 2022 Portfolio in Review

As of Q4 2022, OUP Management Company held 16 positions worth $61.3M, down 4.6% from $64.2M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

OUP Management Company withdrew a net $8.76M in Q4 2022, closing 2 positions and reducing 2 holdings. Its most notable exit was Evolv Technologies, an estimated $1.38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Technology and Industrials.

Against the trend, OUP Management Company opened a new position in Prime Medicine worth $2.25M.

  • OUP Management Company's largest Q4 2022 buy was Prime Medicine: 121,255 shares worth $2.25M.
  • OUP Management Company's biggest Q4 2022 reduction was DICE Therapeutics, Inc. Common Stock, cutting an estimated $8.75M.
  • OUP Management Company fully exited Evolv Technologies in Q4 2022, selling an estimated $1.38M.
  • OUP Management Company's ten largest holdings make up 97% of its $61.3M portfolio in Q4 2022.
  • OUP Management Company opened 1 new position and closed 2 in Q4 2022.
  • OUP Management Company's portfolio value fell 4.6% quarter-over-quarter to $61.3M.

Based on OUP Management Company's 13F filing for Q4 2022, filed 2 Feb 2023.